Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 268

1.

The diversity of the proline-rich domain of pneumococcal surface protein A (PspA): Potential relevance to a broad-spectrum vaccine.

Mukerji R, Hendrickson C, Genschmer KR, Park SS, Bouchet V, Goldstein R, Lefkowitz EJ, Briles DE.

Vaccine. 2018 Oct 29;36(45):6834-6843. doi: 10.1016/j.vaccine.2018.08.045. Epub 2018 Oct 5.

2.

Hyperencapsulated mucoid pneumococcal isolates from patients with cystic fibrosis have increased biofilm density and persistence in vivo.

Dennis EA, Coats MT, Griffin S, Pang B, Briles DE, Crain MJ, Swords WE.

Pathog Dis. 2018 Oct 1;76(7). doi: 10.1093/femspd/fty073.

PMID:
30265307
3.

Macrophage Rac2 Is Required to Reduce the Severity of Cigarette Smoke-induced Pneumonia.

Larson-Casey JL, Gu L, Jackson PL, Briles DE, Hale JY, Blalock JE, Wells JM, Deshane JS, Wang Y, Davis D, Antony VB, Massicano AVF, Lapi SE, Carter AB.

Am J Respir Crit Care Med. 2018 Nov 15;198(10):1288-1301. doi: 10.1164/rccm.201712-2388OC.

PMID:
29897791
4.

Novel Immunoprotective Proteins of Streptococcus pneumoniae Identified by Opsonophagocytosis Killing Screen.

Wang Y, Wen Z, Pan X, Briles DE, He Y, Zhang JR.

Infect Immun. 2018 Aug 22;86(9). pii: e00423-18. doi: 10.1128/IAI.00423-18. Print 2018 Sep.

5.

Inhibition of Autolysis by Lipase LipA in Streptococcus pneumoniae Sepsis.

Kim GL, Luong TT, Park SS, Lee S, Ha JA, Nguyen CT, Ahn JH, Park KT, Paik MJ, Suhkneung-Pyo, Briles DE, Rhee DK.

Mol Cells. 2017 Dec 31;40(12):935-944. doi: 10.14348/molcells.2017.0201. Epub 2017 Dec 26.

6.

Transcutaneous immunization with pneumococcal surface protein A in mice.

Nagano H, Kawabata M, Sugita G, Tsuruhara A, Ohori J, Jimura T, Miyashita K, Kurono Y, Tomonaga K, Briles DE, Fujihashi K.

Laryngoscope. 2018 Mar;128(3):E91-E96. doi: 10.1002/lary.26971. Epub 2017 Dec 11.

PMID:
29226330
7.

Neutrophil Extracellular Traps and Fibrin in Otitis Media: Analysis of Human and Chinchilla Temporal Bones.

Schachern PA, Kwon G, Briles DE, Ferrieri P, Juhn S, Cureoglu S, Paparella MM, Tsuprun V.

JAMA Otolaryngol Head Neck Surg. 2017 Oct 1;143(10):990-995. doi: 10.1001/jamaoto.2017.1320.

8.

Dendritic cell-targeting DNA-based nasal adjuvants for protective mucosal immunity to Streptococcus pneumoniae.

Kataoka K, Fukuyama Y, Briles DE, Miyake T, Fujihashi K.

Microbiol Immunol. 2017 Jun;61(6):195-205. doi: 10.1111/1348-0421.12487. Review.

9.

Pneumococcal pep27 mutant immunization stimulates cytokine secretion and confers long-term immunity with a wide range of protection, including against non-typeable strains.

Kim GL, Choi SY, Seon SH, Lee S, Park SS, Song JY, Briles DE, Rhee DK.

Vaccine. 2016 Dec 12;34(51):6481-6492. doi: 10.1016/j.vaccine.2016.10.071. Epub 2016 Nov 16.

PMID:
27865564
10.

The effects of differences in pspA alleles and capsular types on the resistance of Streptococcus pneumoniae to killing by apolactoferrin.

Mirza S, Benjamin WH Jr, Coan PA, Hwang SA, Winslett AK, Yother J, Hollingshead SK, Fujihashi K, Briles DE.

Microb Pathog. 2016 Oct;99:209-219. doi: 10.1016/j.micpath.2016.08.029. Epub 2016 Aug 26.

PMID:
27569531
11.

Free Sialic Acid Acts as a Signal That Promotes Streptococcus pneumoniae Invasion of Nasal Tissue and Nonhematogenous Invasion of the Central Nervous System.

Hatcher BL, Hale JY, Briles DE.

Infect Immun. 2016 Aug 19;84(9):2607-15. doi: 10.1128/IAI.01514-15. Print 2016 Sep.

12.

PcpA Promotes Higher Levels of Infection and Modulates Recruitment of Myeloid-Derived Suppressor Cells during Pneumococcal Pneumonia.

Walker MM, Novak L, Widener R, Grubbs JA, King J, Hale JY, Ochs MM, Myers LE, Briles DE, Deshane J.

J Immunol. 2016 Mar 1;196(5):2239-48. doi: 10.4049/jimmunol.1402518. Epub 2016 Feb 1.

13.

Pneumolysin plays a key role at the initial step of establishing pneumococcal nasal colonization.

Hotomi M, Yuasa J, Briles DE, Yamanaka N.

Folia Microbiol (Praha). 2016 Sep;61(5):375-83. doi: 10.1007/s12223-016-0445-z. Epub 2016 Jan 23.

PMID:
26803756
14.

Streptococcus pneumoniae induces pyroptosis through the regulation of autophagy in murine microglia.

Kim JY, Paton JC, Briles DE, Rhee DK, Pyo S.

Oncotarget. 2015 Dec 29;6(42):44161-78. doi: 10.18632/oncotarget.6592.

15.

The Effects of CFTR and Mucoid Phenotype on Susceptibility and Innate Immune Responses in a Mouse Model of Pneumococcal Lung Disease.

Dennis EA, Coats MT, Griffin SE, Hale JY, Novak L, Briles DE, Crain MJ.

PLoS One. 2015 Oct 15;10(10):e0140335. doi: 10.1371/journal.pone.0140335. eCollection 2015.

16.

Multivalent Pneumococcal Protein Vaccines Comprising Pneumolysoid with Epitopes/Fragments of CbpA and/or PspA Elicit Strong and Broad Protection.

Chen A, Mann B, Gao G, Heath R, King J, Maissoneuve J, Alderson M, Tate A, Hollingshead SK, Tweten RK, Briles DE, Tuomanen EI, Paton JC.

Clin Vaccine Immunol. 2015 Oct;22(10):1079-89. doi: 10.1128/CVI.00293-15. Epub 2015 Aug 5.

17.

A molecular mucosal adjuvant to enhance immunity against pneumococcal infection in the elderly.

Fukuyama Y, Ikeda Y, Ohori J, Sugita G, Aso K, Fujihashi K, Briles DE, McGhee JR, Fujihashi K.

Immune Netw. 2015 Feb;15(1):9-15. doi: 10.4110/in.2015.15.1.9. Epub 2015 Feb 17. Review.

18.

Nanogel-based pneumococcal surface protein A nasal vaccine induces microRNA-associated Th17 cell responses with neutralizing antibodies against Streptococcus pneumoniae in macaques.

Fukuyama Y, Yuki Y, Katakai Y, Harada N, Takahashi H, Takeda S, Mejima M, Joo S, Kurokawa S, Sawada S, Shibata H, Park EJ, Fujihashi K, Briles DE, Yasutomi Y, Tsukada H, Akiyoshi K, Kiyono H.

Mucosal Immunol. 2015 Sep;8(5):1144-53. doi: 10.1038/mi.2015.5. Epub 2015 Feb 11.

19.

ClpL is a chaperone without auxiliary factors.

Park SS, Kwon HY, Tran TD, Choi MH, Jung SH, Lee S, Briles DE, Rhee DK.

FEBS J. 2015 Apr;282(8):1352-67. doi: 10.1111/febs.13228. Epub 2015 Feb 27.

20.

A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella Typhi.

Kothari N, Kothari S, Choi YJ, Dey A, Briles DE, Rhee DK, Carbis R.

Vaccine. 2015 Feb 4;33(6):783-8. doi: 10.1016/j.vaccine.2014.12.032. Epub 2014 Dec 26.

PMID:
25545593
21.

Evaluation of a vaccine formulation against Streptococcus pneumoniae based on choline-binding proteins.

Miyaji EN, Vadesilho CF, Oliveira ML, Zelanis A, Briles DE, Ho PL.

Clin Vaccine Immunol. 2015 Feb;22(2):213-20. doi: 10.1128/CVI.00692-14. Epub 2014 Dec 17.

22.

Ethanol-induced alcohol dehydrogenase E (AdhE) potentiates pneumolysin in Streptococcus pneumoniae.

Luong TT, Kim EH, Bak JP, Nguyen CT, Choi S, Briles DE, Pyo S, Rhee DK.

Infect Immun. 2015 Jan;83(1):108-19. doi: 10.1128/IAI.02434-14. Epub 2014 Oct 13.

23.

Mouse, but not human, ApoB-100 lipoprotein cholesterol is a potent innate inhibitor of Streptococcus pneumoniae pneumolysin.

Wade KR, Hotze EM, Briles DE, Tweten RK.

PLoS Pathog. 2014 Sep 4;10(9):e1004353. doi: 10.1371/journal.ppat.1004353. eCollection 2014 Sep.

24.

Preparation and testing of a Vi conjugate vaccine using pneumococcal surface protein A (PspA) from Streptococcus pneumoniae as the carrier protein.

Kothari N, Genschmer KR, Kothari S, Kim JA, Briles DE, Rhee DK, Carbis R.

Vaccine. 2014 Sep 29;32(43):5755-60. doi: 10.1016/j.vaccine.2014.08.041. Epub 2014 Aug 27.

PMID:
25171842
25.

Protective properties of a fusion pneumococcal surface protein A (PspA) vaccine against pneumococcal challenge by five different PspA clades in mice.

Piao Z, Akeda Y, Takeuchi D, Ishii KJ, Ubukata K, Briles DE, Tomono K, Oishi K.

Vaccine. 2014 Sep 29;32(43):5607-13. doi: 10.1016/j.vaccine.2014.07.108. Epub 2014 Aug 12.

PMID:
25132335
26.

Pneumococcal PspA and PspC proteins: potential vaccine candidates for experimental otitis media.

Schachern PA, Tsuprun V, Ferrieri P, Briles DE, Goetz S, Cureoglu S, Paparella MM, Juhn S.

Int J Pediatr Otorhinolaryngol. 2014 Sep;78(9):1517-21. doi: 10.1016/j.ijporl.2014.06.024. Epub 2014 Jun 24.

27.

Mapping of epitopes recognized by antibodies induced by immunization of mice with PspA and PspC.

Vadesilho CF, Ferreira DM, Gordon SB, Briles DE, Moreno AT, Oliveira ML, Ho PL, Miyaji EN.

Clin Vaccine Immunol. 2014 Jul;21(7):940-8. doi: 10.1128/CVI.00239-14. Epub 2014 May 7.

28.

Basophil expansion protects against invasive pneumococcal disease in mice.

Bischof A, Brumshagen C, Ding N, Kirchhof G, Briles DE, Gessner JE, Welte T, Mack M, Maus UA.

J Infect Dis. 2014 Jul 1;210(1):14-24. Epub 2014 Jan 26.

PMID:
24470504
29.

A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA).

Genschmer KR, Accavitti-Loper MA, Briles DE.

Vaccine. 2013 Dec 17;32(1):39-47. doi: 10.1016/j.vaccine.2013.10.080. Epub 2013 Nov 6.

30.

Viability and virulence of pneumolysin, pneumococcal surface protein A, and pneumolysin/pneumococcal surface protein A mutants in the ear.

Schachern PA, Tsuprun V, Goetz S, Cureoglu S, Juhn SK, Briles DE, Paparella MM, Ferrieri P.

JAMA Otolaryngol Head Neck Surg. 2013 Sep;139(9):937-43. doi: 10.1001/jamaoto.2013.4104.

31.

Invasive and noninvasive Streptococcus pneumoniae capsule and surface protein diversity following the use of a conjugate vaccine.

Croney CM, Nahm MH, Juhn SK, Briles DE, Crain MJ.

Clin Vaccine Immunol. 2013 Nov;20(11):1711-8. doi: 10.1128/CVI.00381-13. Epub 2013 Sep 4.

32.

Modified opsonization, phagocytosis, and killing assays to measure potentially protective antibodies against pneumococcal surface protein A.

Daniels CC, Kim KH, Burton RL, Mirza S, Walker M, King J, Hale Y, Coan P, Rhee DK, Nahm MH, Briles DE.

Clin Vaccine Immunol. 2013 Oct;20(10):1549-58. doi: 10.1128/CVI.00371-13. Epub 2013 Aug 7.

33.

Retention of structure, antigenicity, and biological function of pneumococcal surface protein A (PspA) released from polyanhydride nanoparticles.

Haughney SL, Petersen LK, Schoofs AD, Ramer-Tait AE, King JD, Briles DE, Wannemuehler MJ, Narasimhan B.

Acta Biomater. 2013 Sep;9(9):8262-71. doi: 10.1016/j.actbio.2013.06.006. Epub 2013 Jun 14.

34.

Asthma and antibodies to pneumococcal virulence proteins.

Zhao H, Jung JA, Briles DE, Kita H, Tsigrelis C, Juhn YJ.

Infection. 2013 Oct;41(5):927-34. doi: 10.1007/s15010-013-0482-3. Epub 2013 Jun 8.

35.

Inactivated pep27 mutant as an effective mucosal vaccine against a secondary lethal pneumococcal challenge in mice.

Choi SY, Tran TD, Briles DE, Rhee DK.

Clin Exp Vaccine Res. 2013 Jan;2(1):58-65. doi: 10.7774/cevr.2013.2.1.58. Epub 2013 Jan 15.

36.

The link between antibodies to OxLDL and natural protection against pneumococci depends on D(H) gene conservation.

Vale AM, Kapoor P, Skibinski GA, Elgavish A, Mahmoud TI, Zemlin C, Zemlin M, Burrows PD, Nobrega A, Kearney JF, Briles DE, Schroeder HW Jr.

J Exp Med. 2013 May 6;210(5):875-90.

37.

PspA family distribution, antimicrobial resistance and serotype of Streptococcus pneumoniae isolated from upper respiratory tract infections in Japan.

Hotomi M, Togawa A, Kono M, Ikeda Y, Takei S, Hollingshead SK, Briles DE, Suzuki K, Yamanaka N.

PLoS One. 2013;8(3):e58124. doi: 10.1371/journal.pone.0058124. Epub 2013 Mar 6.

38.

Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae.

Kong IG, Sato A, Yuki Y, Nochi T, Takahashi H, Sawada S, Mejima M, Kurokawa S, Okada K, Sato S, Briles DE, Kunisawa J, Inoue Y, Yamamoto M, Akiyoshi K, Kiyono H.

Infect Immun. 2013 May;81(5):1625-34. doi: 10.1128/IAI.00240-13. Epub 2013 Mar 4.

39.

Pneumococcal surface protein A inhibits complement deposition on the pneumococcal surface by competing with the binding of C-reactive protein to cell-surface phosphocholine.

Mukerji R, Mirza S, Roche AM, Widener RW, Croney CM, Rhee DK, Weiser JN, Szalai AJ, Briles DE.

J Immunol. 2012 Dec 1;189(11):5327-35. doi: 10.4049/jimmunol.1201967. Epub 2012 Oct 26.

40.

The absence of PspA or presence of antibody to PspA facilitates the complement-dependent phagocytosis of pneumococci in vitro.

Ren B, Li J, Genschmer K, Hollingshead SK, Briles DE.

Clin Vaccine Immunol. 2012 Oct;19(10):1574-82. Epub 2012 Aug 1.

41.

PspA family distribution, unlike capsular serotype, remains unaltered following introduction of the heptavalent pneumococcal conjugate vaccine.

Croney CM, Coats MT, Nahm MH, Briles DE, Crain MJ.

Clin Vaccine Immunol. 2012 Jun;19(6):891-6. doi: 10.1128/CVI.05671-11. Epub 2012 Apr 25.

42.

Nontypeable pneumococci can be divided into multiple cps types, including one type expressing the novel gene pspK.

Park IH, Kim KH, Andrade AL, Briles DE, McDaniel LS, Nahm MH.

MBio. 2012 Apr 24;3(3). pii: e00035-12. doi: 10.1128/mBio.00035-12. Print 2012.

43.

Hepatic induction of cholesterol biosynthesis reflects a remote adaptive response to pneumococcal pneumonia.

Weber M, Lambeck S, Ding N, Henken S, Kohl M, Deigner HP, Enot DP, Igwe EI, Frappart L, Kiehntopf M, Claus RA, Kamradt T, Weih D, Vodovotz Y, Briles DE, Ogunniyi AD, Paton JC, Maus UA, Bauer M.

FASEB J. 2012 Jun;26(6):2424-36. doi: 10.1096/fj.11-191957. Epub 2012 Mar 13.

PMID:
22415311
44.

Specific immunization strategies against oxidized low-density lipoprotein: a novel way to reduce nonalcoholic steatohepatitis in mice.

Bieghs V, van Gorp PJ, Walenbergh SM, Gijbels MJ, Verheyen F, Buurman WA, Briles DE, Hofker MH, Binder CJ, Shiri-Sverdlov R.

Hepatology. 2012 Sep;56(3):894-903. doi: 10.1002/hep.25660. Epub 2012 Jul 6.

45.

CCL5-independent helper T lymphocyte responses to immuno-dominant pneumococcal surface protein A epitopes.

Singh R, Singh S, Briles DE, Taub DD, Hollingshead SK, Lillard JW Jr.

Vaccine. 2012 Feb 1;30(6):1181-90. doi: 10.1016/j.vaccine.2011.12.020. Epub 2011 Dec 14.

46.

Streptococcus pneumoniae pep27 mutant as a live vaccine for serotype-independent protection in mice.

Kim EH, Choi SY, Kwon MK, Tran TD, Park SS, Lee KJ, Bae SM, Briles DE, Rhee DK.

Vaccine. 2012 Mar 2;30(11):2008-19. doi: 10.1016/j.vaccine.2011.11.073. Epub 2011 Dec 7.

PMID:
22154770
47.

Maternal immunization with pneumococcal surface protein A protects against pneumococcal infections among derived offspring.

Kono M, Hotomi M, Hollingshead SK, Briles DE, Yamanaka N.

PLoS One. 2011;6(10):e27102. doi: 10.1371/journal.pone.0027102. Epub 2011 Oct 31.

48.

Heat-shock protein ClpL/HSP100 increases penicillin tolerance in Streptococcus pneumoniae.

Tran TD, Kwon HY, Kim EH, Kim KW, Briles DE, Pyo S, Rhee DK.

Adv Otorhinolaryngol. 2011;72:126-8. doi: 10.1159/000324658. Epub 2011 Aug 18.

PMID:
21865709
49.

Protection of pneumococcal infection by maternal intranasal immunization with pneumococcal surface protein A.

Hotomi M, Kono M, Hollingshead SK, Briles DE, Yamanaka N.

Adv Otorhinolaryngol. 2011;72:121-5. doi: 10.1159/000324656. Epub 2011 Aug 18.

PMID:
21865708
50.

Elicitation of mucosal immunity by proteins of Streptococcus pneumoniae.

Briles DE, Miyaji E, Fukuyama Y, Ferreira DM, Fujihashi K.

Adv Otorhinolaryngol. 2011;72:25-7. doi: 10.1159/000324589. Epub 2011 Aug 18.

PMID:
21865682

Supplemental Content

Loading ...
Support Center